| BRAHMI, Mehdi |
RAR-Immune, NCT04741438: Efficacy of the Combination of Nivolumab and Ipilimumab as a Treatment in Patients With Sarcoma of Rare Subtype |
|
|
| Recruiting | 3 | 96 | Europe | Nivolumab and IPILIMUMAB, Pazopanib Oral Tablet [Votrient] | Centre Leon Berard | Sarcoma | 02/25 | 08/25 | | |
| Recruiting | 3 | 250 | Europe, Canada, Japan, US, RoW | Surgery, Preoperative chemotherapy, neoadjuvant chemotherapy | European Organisation for Research and Treatment of Cancer - EORTC, Canadian Cancer Trials Group, ECOG-ACRIN Cancer Research Group, Anticancer Fund, Belgium, Australia and New Zealand Sarcoma Association, Japan Clinical Oncology Group | Retroperitoneal Sarcoma, Liposarcoma, Leiomyosarcoma | 04/27 | 04/28 | | |
| Completed | 2 | 127 | Europe | Regorafenib, stivarga, Placebo | Centre Oscar Lambret | Metastatic Soft Tissue Sarcoma | 03/24 | 09/24 | | |
MOST plus, NCT02029001: Adapting Treatment to the Tumor Molecular Alterations for Patients With Advanced Solid Tumors: MyOwnSpecificTreatment |
|
|
| Recruiting | 2 | 900 | Europe | Nilotinib (400 mg BID), Open cohort, Everolimus (10 mg QD), Closed cohort, Sorafenib (400 mg BID), Lapatinib (1500 mg QD), Pazopanib (800 mg QD), Olaparib (300 mg BID), Durvalumab + Tremelimumab | Centre Leon Berard, National Cancer Institute, France | Malignant Solid Neoplasms | 01/26 | 10/27 | | |
GIST-TEN, NCT05009927: Efficiency of Imatinib Treatment After 10 Years of Treatment in Patients With Gastrointestinal Stromal Tumours (GIST) (Gist-Ten) |
|
|
| Recruiting | 2 | 50 | Europe | Imatinib tablets, Glivec | Centre Leon Berard | Metastatic Gastrointestinal Stromal Tumor (GIST), C-KIT Mutation, Advanced Gastrointestinal Stromal Tumor (GIST) | 01/25 | 01/27 | | |
ATEZOGIST, NCT05152472: A Prospective, Randomized, Multicenter, Comparative Study of the Efficacy of Imatinib Resumption Combined With Atezolizumab Versus Imatinib Resumption Alone in Patients With Unresectable Advanced Gastrointestinal Stromal Tumors (GIST) After Failure of Standard Treatments |
|
|
| Recruiting | 2 | 110 | Europe | Atezolizumab 1200 mg, Tecentriq®, Imatinib 400 MG, Glivec® | Centre Leon Berard | Unresectable Gastrointestinal Stromal Tumor (GIST), Locally Advanced Gastrointestinal Stromal Tumor (GIST), Metastatic Gastrointestinal Stromal Tumor | 10/27 | 10/27 | | |
| Recruiting | 2 | 66 | Europe | Doxorubicin, Ifosfamide, INCMGA00012, Retifanlimab | Institut Bergonié, Incyte Biosciences International Sàrl | Resectable Sarcoma | 03/25 | 10/27 | | |
REGOMAIN, NCT04698785: Efficacy of Regorafenib Combined With Best Supportive Care as Maintenance Treatment in High Grade Bone Sarcomas Patients |
|
|
| Recruiting | 2 | 36 | Europe | Treatment by regorafenib and best supportive care, Experimental arm | Centre Leon Berard | Bone Sarcoma, Osteosarcoma | 07/26 | 07/26 | | |
| Recruiting | 1/2 | 210 | Europe, US, RoW | CPI-0209 | Constellation Pharmaceuticals | Advanced Solid Tumor, Diffuse Large B Cell Lymphoma, Lymphoma, T-Cell, Mesothelioma, Malignant, Prostatic Neoplasms, Castration-Resistant, Endometrial Cancer, Ovarian Clear Cell Carcinoma | 12/25 | 03/26 | | |
SPARTO, NCT05210413: Spartalizumab and Low-dose PAzopanib in Refractory or Relapsed Solid TumOrs of Pediatric and Adults |
|
|
| Recruiting | 1/2 | 59 | Europe | Spartalizumab in Pediatric cohort, Low-dose Pazopanib in Pediatric Cohort, Spartalizumab in Adult cohort, Low-dose Pazopanib in Adult Cohort | University Hospital, Bordeaux, National Cancer Institute, France, Fondation ARC, Novartis | Refractory or Recurrent Solid Tumor | 11/26 | 11/27 | | |
TRAHD, NCT03714958: Trametinib + HDM201 in CRC Patients With RAS/RAF Mutant and TP53 Wild-type Advanced/Metastatic Colorectal Cancer Mutant and TP53 Wild-type |
|
|
| Completed | 1 | 12 | Europe | HDM201, Trametinib | Centre Leon Berard, Novartis | Colorectal Cancer, Advanced Cancer, Metastatic Cancer | 09/23 | 09/23 | | |
NCT03715933: Phase 1 Study of INBRX-109 in Subjects with Locally Advanced or Metastatic Solid Tumors Including Sarcomas |
|
|
| Recruiting | 1 | 321 | Europe, US | INBRX-109, Carboplatin, Cisplatin, Pemetrexed, 5-fluorouracil, Irinotecan, Temozolomide | Inhibrx Biosciences, Inc | Colorectal Adenocarcinoma, Ewing Sarcoma | 06/26 | 12/26 | | |
NCT04936178: A Study of NB003 in Patients With Advanced Malignancies |
|
|
| Recruiting | 1 | 258 | Europe, US, RoW | NB003 tablets | Ningbo Newbay Technology Development Co., Ltd | Advanced Solid Tumor | 07/25 | 12/25 | | |
MEDISARC-SBRT, NCT05821231: Study Evaluating the Safety and Efficacy of MEDI5752 in Combination With Stereotactic Radiotherapy in Patients With Metastatic Sarcoma |
|
|
| Recruiting | 1 | 20 | Europe | SBRT + MEDI5752 | Institut Claudius Regaud, National Cancer Institute, France, AstraZeneca | Soft Tissue Sarcoma | 11/27 | 11/27 | | |
RNASARC, NCT03375437: - Molecular Screening Program of Soft Tissue Sarcomas With Complex Genomic Profile to Detect NTRK1/2/3, ROS1 or ALK Gene Fusions. |
|
|
| Active, not recruiting | N/A | 376 | Europe | Blood and tumor samples | Centre Leon Berard, Hoffmann-La Roche | Soft Tissue Sarcoma, Advanced Cancer, Metastatic Cancer | 12/24 | 12/25 | | |
| Recruiting | N/A | 150 | Europe | Cryoablation, Chemotherapy drug | University Hospital, Strasbourg, France, Direction Générale de l'Offre des Soins (DGOS) | Desmoid Tumor | 03/27 | 06/29 | | |
PASCA, NCT04671693: A Post-treatment Program to Identify and Manage Complications Related to Oncology or Hematology Treatments in Cancer Survivors. |
|
|
| Recruiting | N/A | 858 | Europe | PASCA intervention | Centre Leon Berard, Malakoff-Humanis, Fondation Apicil, Fédération Leucémie Espoir, Biogaran, Le défi Anthony, Novartis, Roche Pharma AG | Late Effects, Testicular Germ Cell Tumor Mixed, Non-Metastatic Breast Carcinoma, Soft Tissue Sarcoma, Adult, Stage IIC, Osteosarcoma, Ewing's Sarcoma, Acute Myeloid Leukemia, Hodgkin Disease, Non Hodgkin Lymphoma | 01/28 | 04/28 | | |
| Active, not recruiting | N/A | 25 | Europe | Patient treated by Avapritinib in real life | Centre Leon Berard, Blueprint Medicines Corporation | GIST, GIST, Malignant, PDGFR-Alpha D842V | 04/24 | 12/24 | | |
